Dr. Michael Adams appointed Interim Associate Dean, Undergraduate Studies (Life Sciences, Biochemistry and BHSc)
On the recommendation of Dean Jane Philpott, Teri Shearer, Interim Provost and Vice-Principal (Academic) has appointed Dr. Michael Adams as Interim Associate Dean, Undergraduate Studies (Life Sciences, Biochemistry, BHSc), effective July 1, 2023 for a two-year term.
This is a new position that merges the former roles of Associate Dean, Life Sciences and Biochemistry and leadership of the Bachelor of Health Sciences program. Dr. Adams will report to the new role of Vice-Dean, Basic and Public Health Sciences and will be supported by three new Directors: Dr. Robert Campbell for Life Sciences, Dr. Nikki Philbrook for the BHSc program, and Dr. Laura van Staalduinen for Biochemistry.
Dr. Philpott wishes to thank Dr. Louise Winn for her contributions as Associate Dean, Life Sciences and Biochemistry over the past five years. Her academic leadership, passion and commitment to student well-being and accomplishments are a testament to the strength and success of these programs. In particular, the School is grateful for her careful navigation of the educational challenges posed by the COVID-19 pandemic and for her thoughtful consideration into the structure needed to ensure the ongoing success of these cornerstone programs.
Dr. Adams is a renowned researcher, educator and academic builder who has spent the past 35 years of his career at Queen’s Health Sciences in a number of leadership roles. Most recently, he was the founder and inaugural Director of the Bachelor of Health Sciences Program (online and on campus) and led the creation of the Faculty’s Course Development Unit to build online and blended course modules for the programs. He won a Principal’s Education Leadership Award in 2019 for his many contributions in transforming educational curriculum across QHS.
He is a biomedical scientist with a research focus on developing new strategies to prevent and treat kidney and cardiovascular disease, as well as sexual dysfunction, and other conditions involving peripheral vascular diseases. He has successfully supervised more than 80 graduate students during his career. Widely published with numerous awards, he is the founder of two start-up companies, holds 16 patents and successfully developed a drug that was marketed on a global scale.
This announcement was initially posted by Queen's Health Sciences.